SCHEMBL12484664

SCHEMBL12484664

CCCc1cc(N2CCCCC2CCO)nc(Nc2cccc(SC)c2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK2 P24941 7/20 0.44
▸ CDK9 P50750 5/20 0.44
▸ CCNE1 P24864 3/20 0.44
▸ CDK7 P50613 3/20 0.44
▸ CCNT1 O60563 2/20 0.44
▸ CCNK O75909 2/20 0.44
▸ CCNH P51946 2/20 0.44
▸ MNAT1 P51948 2/20 0.44
▸ CDK13 Q14004 2/20 0.44
▸ CDK12 Q9NYV4 2/20 0.44
▸ CDK1 P06493 5/20 0.38
▸ CCNA2 P20248 3/20 0.38
▸ CCNA1 P78396 3/20 0.38
▸ CCNB2 O95067 2/20 0.38
▸ CCNB1 P14635 2/20 0.38
▸ CCNB3 Q8WWL7 2/20 0.38
▸ HCRTR1 O43613 1/20 0.37
▸ HCRTR2 O43614 1/20 0.37
▸ CDK5 Q00535 4/20 0.36
▸ GSK3A P49840 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL17698262 0.99 CDK2 (0.43) CDK2CDK9CCNE1CDK7CCNT1
SCHEMBL12486219 0.91 CDK2 (0.40) CDK2CDK9CCNE1CDK7CCNT1
SCHEMBL12484711 0.90 HCRTR1 (0.40) CDK2CDK1CCNA2CCNA1CCNB2
SCHEMBL12484716 0.90 HCRTR1 (0.40) CDK2CDK1CCNA2CCNA1CCNB2
SCHEMBL12486147 0.88 CDK1 (0.46) CDK2CDK9CCNE1CDK7CCNT1
SCHEMBL12485319 0.86 GBA1 (0.48) CDK2CDK9CCNE1CDK7CCNT1
SCHEMBL12485949 0.85 CDK2 (0.43) CDK2CDK9CCNE1CDK7CCNT1
SCHEMBL12485906 0.85 MAPT (0.46) CDK2CDK9CCNE1CDK7CCNT1
SCHEMBL12485077 0.85 ADORA2A (0.42) CDK2CDK1CCNA2CCNA1CCNB2
SCHEMBL12485074 0.85 ADORA2A (0.42) CDK2CDK1CCNA2CCNA1CCNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10640490-B2 Diaminopyrimidine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2020-05-05 — — US claimed
US-20180072705-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2018-03-15 — — US claimed
US-9850227-B2 Diaminopyrimidine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2017-12-26 — — US claimed
EP-2678331-B1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORP (KR) 2016-04-27 — — EP claimed
EP-2678331-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF Yuhan Corporation (KR) 2014-01-01 — — EP claimed
US-20130331377-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2013-12-12 — — US claimed
WO-2012115478-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2012-08-30 — — WO claimed
US-10640490-B2 Diaminopyrimidine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2020-05-05 — — US disclosed
US-20180072705-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2018-03-15 — — US disclosed
US-9850227-B2 Diaminopyrimidine derivatives and processes for the preparation thereof YUHAN CORPORATION (KR) 2017-12-26 — — US disclosed
EP-2678331-B1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORP (KR) 2016-04-27 — — EP disclosed
EP-2678331-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF Yuhan Corporation (KR) 2014-01-01 — — EP disclosed
US-20130331377-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2013-12-12 — — US disclosed
WO-2012115478-A2 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF YUHAN CORPORATION (KR) 2012-08-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331377-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF HRH2, GIPR, SSTR4 CDK2 1458/4885CDK9 557/4885CCNE1 2906/4885
US-10640490-B2 Diaminopyrimidine derivatives and processes for the preparation thereof HRH2, GIPR, SSTR4 CDK2 1458/4885CDK9 557/4885CCNE1 2906/4885
US-20180072705-A1 DIAMINOPYRIMIDINE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF HRH2, GIPR, SSTR4 CDK2 1458/4885CDK9 557/4885CCNE1 2906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback